4DMedical Limited (ASX:4DX): Respiratory Imaging Products and FY26 Commercial Priorities

Aditi Sarkar

02 November 2026 06:10 PM AEDT

4DMedical Limited (ASX:4DX): Respiratory Imaging Products and FY26 Commercial Priorities

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

4DMedical Limited (ASX:4DX) closed at AUD 2.635 on 2 November 2026.
Official company disclosures describe its 2026 operating and financial position.
Recent updates identify key operating or product developments.
Further financial and operational reporting remains relevant.

4DMedical Limited (ASX:4DX) develops medical imaging software that translates lung scan data into measurements of respiratory function. Its products are designed for clinical assessment of ventilation, perfusion and respiratory disease. Shares closed at AUD 2.635 on 2 November 2026, as the company continued to report on its medical imaging commercialisation activities.

Company Business and Operating Model

The company identifies XV Technology as its foundational four-dimensional lung imaging technology and CT:VQ as a ventilation-perfusion analysis solution based on standard CT scans. Its software-led approach is intended to work with existing imaging systems. The distinction between technical clearance and commercial adoption is material: clinicians and institutions must integrate products into practical workflows before sales can be sustained.

Recent 2026 Developments

4DMedical lists the United States and Australia among the markets in which it pursues adoption of its respiratory imaging software. Operating in healthcare requires interactions among clinicians, radiology departments, hospital procurement teams and reimbursement systems. Its commercial model depends not only on the imaging capability but also on hospitals deciding to deploy the technology.

The company published its FY2026 full-year results and Annual Report on 30 September 2026. It also published an activities report and Appendix 4C for the June 2026 quarter on 30 July. Those materials are relevant for assessing the progression of revenue, receipts, expenditure and available funding. This article does not assume financial amounts that cannot be substantiated from those filings.

Financial Performance and Sector Context

Its investor information describes a regulatory-cleared product portfolio and an expanding focus on the US healthcare market. CT:VQ and its associated quantitative imaging capabilities are central to the stated commercial strategy. A clearance, however, does not ensure a specified number of installations, reimbursed examinations or contracted customers.

Imaging software can generate recurring receipts where providers subscribe to solutions, but the pace of implementation depends on contracting and deployment decisions. Technical validation, product Training and interoperability may also affect the timing between a customer agreement and widespread clinical use. These considerations are important for interpreting commercial updates in a still-developing market.

Operating cash expenditure, customer receipts and Liquidity remain particularly relevant for 4DMedical Limited (ASX:4DX). Research, regulatory, clinical evidence and sales activity require spending before the full effect of deployments is reflected in revenue. The company states that it generally intends to reinvest cash flows in its business rather than prioritise near-term dividends.

Risks to Consider

Healthcare technology markets are exposed to reimbursement decisions, institutional purchasing cycles, product competition and regulatory requirements. Adoption can vary across health systems even where comparable clinical needs exist. Product development may also introduce new validation and approval requirements. These are commercial and operating risks rather than forecasts of a particular outcome.

What to Watch Next

Investors monitoring 4DMedical Limited (ASX:4DX) can compare reported customer deployment progress with changes in cash receipts and expenditure. Future quarterly cash-flow statements, audited annual financial information and product-specific commercial updates can help establish whether the strategy is translating into measurable activity.

Key Insights

4DMedical Limited (ASX:4DX) is developing a software-based respiratory imaging business around quantitative lung assessment. Its 2026 reports and product disclosures identify the technologies and commercial workstreams under review. A balanced assessment depends on verified deployment, income and liquidity data rather than assuming that clinical applications immediately translate into financial returns.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.